The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

				OMB APPROVAL
UNITED STATES SECURITIES AND EXCHAN Washington, D.C. 20549			E COMMISSION	OMB 3235-
		on, D.C. 20549 DRM D		Number: 0076
	10			Estimated average
	Notice of Exempt	Offering of Securi	ties	burden
				hours per response: 4.00
1. Issuer's Identity				
CIK (Filer ID Num	ber) Previous Names	X None		Entity Type
0001620463			X Corp	oration
Name of Issuer			-	ted Partnership
M3 Biotechnology, Inc.			Limi	ted Liability Company
Jurisdiction of			Gene	eral Partnership
Incorporation/Organ	ization		Busi	ness Trust
DELAWARE Voor of Incomposed	ion/Organization		Othe	r (Specify)
Year of Incorporat	ion/Organization			
X Over Five Years Ago	anifer Vaar)			
Within Last Five Years (Sp Yet to Be Formed	pecify rear)			
2. Principal Place of Business	and Contact Information			
Name o	f Issuer			
M3 Biotechnology, Inc.				
Street A	ddress 1		Street Address	2
4000 MASON ROAD, SUIT	E 300	BOX 352141		
City	State/Province/Country	ZIP/Posta	lCode Phone	e Number of Issuer
SEATTLE	WASHINGTON	981952141	509592	7191
3. Related Persons				
Last Name	Firs	st Name	Midd	lle Name
Kawas	Leen			
Street Address 1		Address 2		
4000 Mason Road, Suite 300	Box 352141			
City		vince/Country		ostalCode
Seattle	WASHINGTON		981952141	
Relationship: X Executive C	Officer X Director Promot	er		
Clarification of Response (if I	Necessary):			
Last Name	Firs	st Name	Midd	lle Name
Fluke	John	···· ·		
Street Address 1	Street	Address 2		
4000 Mason Road, Suite 300	Box 3521414			

City	State/Province/Cour	itry 2
Seattle	WASHINGTON	981952141
Relationship: X Executi	ive Officer X Director Promoter	

ZIP/PostalCode

Clarification of Response (if Necessary):

Last Name **First Name Middle Name** Harding Joseph **Street Address 1 Street Address 2** 4000 Mason Road, Suite 300 Box 3521414 City State/Province/Country **ZIP/PostalCode** Seattle WASHINGTON 981952141 Relationship: Executive Officer X Director Promoter Clarification of Response (if Necessary): Last Name **First Name Middle Name** Montgomery Bruce **Street Address 1 Street Address 2** Box 352141 4000 Mason Road, Suite 300 City State/Province/Country **ZIP/PostalCode** Seattle WASHINGTON 981952141 Relationship: Executive Officer X Director Promoter Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Montgomery	Michael	
Street Address 1	Street Address 2	
4000 Mason Road, Suite 300	Box 352141	
City	State/Province/Country	ZIP/PostalCode
Seattle	WASHINGTON	981952141
Relationship: Executive Officer	X Director Promoter	

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Banking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund Is the issuer registered as an investment company under the Investment Company Act of 1940? Yes No Other Banking & Financial Services Business Services Energy Coal Mining Electric Utilities Energy Conservation Environmental Services	Health Care X Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care Manufacturing Real Estate Commercial Construction REITS & Finance Residential Other Real Estate	Retailing Restaurants Technology Computers Telecommunications Other Technology Travel Airlines & Airports Lodging & Conventions Tourism & Travel Services Other Travel
--	---	--

Oil & Gas

Other Energy

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Investment Company A	Act Section 3(c)
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)
Rule 504 (b)(1)(i) Bule 504 (b)(1)(ii)	Section $3(c)(2)$	Section 3(c)(10)
Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	Section $3(c)(3)$	Section $3(c)(11)$
Rule 505	Section $3(c)(4)$	Section $3(c)(12)$
X Rule 506(b)	Section $3(c)(5)$	Section $3(c)(13)$
Rule 506(c)	Section $3(c)(6)$	Section 3(c)(14)
Securities Act Section 4(a)(5)	Section 3(c)(7)	

7. Type of Filing

New Notice Date of First Sale 2015-10-27 First Sale Yet to Occur

- X Amendment
- 8. Duration of Offering

Does the Issuer intend this offering to last more than one year? X Yes No

9. Type(s) of Securities Offered (select all that apply)

X Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)
10. Business Combination Transaction	

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient

(Associated) Broker or Dealer X None Street Address 1 Recipient CRD Number X None (Associated) Broker or Dealer CRD Number X None Street Address 2 State/Province/Country

All States Foreign/non-US

ZIP/Postal Code

34

13. Offering and Sales Amounts

Total Offering Amount	\$11,000,000 USD or	Indefinite
Total Amount Sold	\$10,073,475 USD	
Total Remaining to be Sold	\$926,525 USD or	Indefinite

Clarification of Response (if Necessary):

State(s) of Solicitation (select all that apply)

Check "All States" or check individual States

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
M3 Biotechnology, Inc.	/s/ Leen Kawas	Leen Kawas	Chief Executive Officer	2017-04-19

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.